Erratum: Department of Error (The Lancet (2017) 389(10075) (1195–1205), (S0140673616326162), (10.1016/S0140-6736(16)32616-2));11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

The Lancet

Volumn 389, Issue 10075, 2017, Pages 1195-1205

  Cameron, David ^a   Piccart Gebhart, Martine J ^b   Gelber, Richard D ^c,d   Procter, Marion ^e   Goldhirsch, Aron ^f   de Azambuja, Evandro ^b   Castro, Gilberto ^g   Untch, Michael ^h   Smith, Ian ⁱ   Gianni, Luca ^j   Baselga, Jose ^k   Al Sakaff, Nedal ^l   Lauer, Sabine ^l   McFadden, Eleanor ^e   Leyland Jones, Brian ^m   Bell, Richard ⁿ   Dowsett, Mitch ⁱ   Jackisch, Christian ^o  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d HARVARD MEDICAL SCHOOL   (United States)

^e FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h HELIOS KLINIKUM BERLIN BUCH   (Germany)

ⁱ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^j SAN RAFFAELE HOSPITAL   (Italy)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l F HOFFMANN LA ROCHE LTD   (Switzerland)

^m Avera Health   (United States)

ⁿ DEAKIN UNIVERSITY   (Australia)

^o SANA KLINIKUM OFFENBACH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; HORMONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; DRUG ADMINISTRATION; HEART DISEASE; KAPLAN MEIER METHOD; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; RECEPTOR, ERBB-2; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 85013031141     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)32771-5     Document Type: Erratum

References (18)

1. 1 Piccart-Gebhart, MJ, Procter, M, Leyland-Jones, B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005), 1659–1672.
2. 2 Romond, EH, Perez, EA, Bryant, J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005), 1673–1684.
3. 3 Slamon, D, Eiermann, W, Robert, N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365 (2011), 1273–1283.
4. 4 Smith, I, Procter, M, Gelber, RD, et al., for the HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007), 29–36.
5. 5 Gianni, L, Dafni, U, Gelber, RD, et al., for the Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12 (2011), 236–244.
6. 6 Perez, EA, Romond, EH, Suman, VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29 (2011), 3366–3373.
7. 7 Goldhirsch, A, Gelber, RD, Piccart-Gebhart, MJ, et al., for the Herceptin Adjuvant (HERA) Trial Study Team. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382 (2013), 1021–1028.
8. 8 Hudis, CA, Barlow, WE, Costantino, JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25 (2007), 2127–2132.
9. 9 Kaplan, EL, Meier, P, Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958), 457–481.
10. 10 Cox, DR, Regression models and life-tables (with discussion). J R Stat Soc Series B 34 (1972), 187–220.
11. 11 Kalbfleisch, JD, Prentice, RL, The statistical analysis of failure time data, 2nd edn., 2002, Wiley, Hoboken, NJ, 193–217 247–77.
12. 12 Piccart-Gebhart, M, Holmes, E, Baselga, J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 34 (2016), 1034–1042.
13. 13 de Azambuja, E, Holmes, AP, Piccart-Gebhart, M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 15 (2014), 1137–1146.
14. 14 Gianni, L, Pienkowski, T, Im, YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17 (2016), 791–800.
15. 15 Swain, SM, Baselga, J, Kim, SB, et al., for the CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372 (2015), 724–734.
16. 16 Chan, A, Delaloge, S, Holmes, FA, et al., for the ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17 (2016), 367–377.
17. 17 Bianchini, G, Gianni, L, The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 15 (2014), e58–e68.
18. 18 de Azambuja, E, Procter, MJ, van Veldhuisen, DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1–01). J Clin Oncol 32 (2014), 2159–2165.